Vancouver, British Columbia--(Newsfile Corp. - May 25, 2021) - MYM Nutraceuticals Inc. (CSE: MYM) (OTCQB: MYMMF) ("MYM" or the "Company") published a notice of meeting and record date for the upcoming special meeting of shareholders of MYM (the "Meeting") disclosing that the record date will be May 31, 2021 and the Meeting will be on July 5, 2021. At the Meeting, shareholders will be asked to consider and vote on a special resolution approving, among other things, the arrangement agreement entered into on March 31, 2021 between MYM, IM Cannabis Corp., and Trichome Financial Corp. (the "Arrangement Agreement") and the plan of arrangement to be completed under the Business Corporations Act (British Columbia) pursuant to the Arrangement Agreement.
The Company also issued 113,893,254 common shares in the capital of the Company ("Common Shares") pursuant to a right of conversion of 113,893,254 Class A Special Shares ("Special Shares") in the capital of MYM International Brands Inc., a wholly owned subsidiary of the Company. The Special Shares were issued in connection with the acquisition of Highland Grow Inc. on July 31, 2020. Following the issuance, Cultivator Catalyst Corp., a wholly owned subsidiary of Biome Grow Inc., holds voting control over more than 20% of the issued and outstanding Common Shares.
If you have any questions in connection to the meeting or voting, please feel free to contact our Proxy Solicitation and Information Agent, D.F. King Canada by email at or by calling toll free in North America 1 (800) 232-0316 or by calling direct (Bank, Brokers and other intermediaries call collect outside of North America) at 1 (416) 682-3825.
About MYM Nutraceuticals Inc.
MYM is a Canadian cultivator, processor, and distributor of premium cannabis via its two wholly owned subsidiaries - SublimeCulture Inc., in Laval, QC and Highland Grow Inc., in Antigonish, NS. MYM shares trade in Canada, Germany and the United States under the following symbols: (CSE: MYM) (OTCQB: MYMMF) (FSE: 0MY) (DEU: 0MY) (MUN: 0MY) (STU: 0MY).
ON BEHALF OF THE MYM BOARD
Michael Wiener, CEO
MYM Nutraceuticals Inc.
Robin Linden, Chief Marketing Officer
(778)-522-2261
Keep up to date with MYM on our social media channels:
Twitter:
Facebook:
Instagram:
Linkedin:
Disclaimer for Forward-Looking Information
This press release contains "forward-looking information" within the meaning of applicable securities laws about MYM's current expectations, estimates and projections about the future, based on certain assumptions made in light of experiences and perceptions of historical trends. Although MYM believes that the expectations represented by such forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Investors should not place undue reliance on forward-looking information, which is inherently uncertain. Actual results may materially differ from the expectations represented in the forward-looking information in this press release.
Forward-looking information is sometimes, but not always, identified by the use of words such as "seek", "anticipate", "believe", "plan", "estimate", "expect", "likely" and "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. Forward-looking information in this press release includes, but is not limited to, statements about the timing of the Meeting and the voting control of Cultivator Catalyst Corp.
Developing forward-looking information involves reliance on many assumptions and considerations of certain risks and uncertainties, some of which are specific to MYM, and others that apply to the industry generally. Some of the risks and other factors which could cause actual results to differ materially from those expressed in the forward looking statements contained in this press release, include, but are not limited to, the risk factors included under the heading "Risk Factors" in the annual information form of MYM dated September 26, 2020 and under the heading "Risk Factors" in the MD&A for the three months ended February 28, 2021, both of which are available on .
To view the source version of this press release, please visit
